G T Russo1, A M Labate2, A Giandalia2, E L Romeo2, P Villari2, A Alibrandi3, G Perdichizzi2, D Cucinotta2. 1. Department of Clinical and Experimental Medicine, Policlinico Universitario G. Martino, University of Messina, Via C. Valeria, 98121, Messina, Italy. giuseppina.russo@unime.it. 2. Department of Clinical and Experimental Medicine, Policlinico Universitario G. Martino, University of Messina, Via C. Valeria, 98121, Messina, Italy. 3. Department of Economical, Business and Environmental Sciences and Quantitative Methods, University of Messina, Messina, Italy.
Abstract
AIM: In addition to the effects on glycemic control and body weight, GLP-1 receptor agonists may favorably affect other major cardiovascular disease (CVD) risk factors, although currently available data are still sparse. In this retrospective study, we evaluated the effects of 12-month treatment with liraglutide on major CVD risk factors in 115 type 2 diabetes outpatients (60 men and 55 women), on stable hypoglycemic, anti-hypertensive and/or lipid-lowering therapy. METHODS: Clinical and anthropometric data, metabolic and lipid profile, as well as the Visceral Adiposity Index (VAI), an obesity-related CVD risk factor, were measured in all participants at baseline and after 12-month treatment. RESULTS: Treatment with liraglutide was associated with a significant reduction from baseline values of fasting blood glucose (-42.1 mg/dl, P < 0.05), HbA1c (-1.5 %, -17 mmol/mol, P < 0.05), body weight (-7.1 kg, P < 0.05), waist circumference (-6.8 cm, P < 0.001), total-cholesterol (-27.4 mg/dl, P < 0.05), LDL-cholesterol (-25.4 mg/dl, P < 0.05), triglycerides (-56.1 mg/dl, P < 0.05), and non-HDL-C (-36.6 mg/dl, P < 0.05) and an increase of HDL-cholesterol concentrations (+9.3 mg/dl, P < 0.001), a significant reduction in both systolic and diastolic blood pressure (-14.7 mmHg, P < 0.001 and -9.0 mmHg, P < 0.05, respectively) and a decrease of VAI values (-1.6, P < 0.001). All these differences were independent of changes in BMI and comparable in men and women. CONCLUSIONS: In conclusion, 12-month treatment with liraglutide in add-on to on-going hypoglycemic therapy significantly ameliorates all major CVD risk factors and reduces cardiometabolic risk, as estimated by VAI values.
AIM: In addition to the effects on glycemic control and body weight, GLP-1 receptor agonists may favorably affect other major cardiovascular disease (CVD) risk factors, although currently available data are still sparse. In this retrospective study, we evaluated the effects of 12-month treatment with liraglutide on major CVD risk factors in 115 type 2 diabetes outpatients (60 men and 55 women), on stable hypoglycemic, anti-hypertensive and/or lipid-lowering therapy. METHODS: Clinical and anthropometric data, metabolic and lipid profile, as well as the Visceral Adiposity Index (VAI), an obesity-related CVD risk factor, were measured in all participants at baseline and after 12-month treatment. RESULTS: Treatment with liraglutide was associated with a significant reduction from baseline values of fasting blood glucose (-42.1 mg/dl, P < 0.05), HbA1c (-1.5 %, -17 mmol/mol, P < 0.05), body weight (-7.1 kg, P < 0.05), waist circumference (-6.8 cm, P < 0.001), total-cholesterol (-27.4 mg/dl, P < 0.05), LDL-cholesterol (-25.4 mg/dl, P < 0.05), triglycerides (-56.1 mg/dl, P < 0.05), and non-HDL-C (-36.6 mg/dl, P < 0.05) and an increase of HDL-cholesterol concentrations (+9.3 mg/dl, P < 0.001), a significant reduction in both systolic and diastolic blood pressure (-14.7 mmHg, P < 0.001 and -9.0 mmHg, P < 0.05, respectively) and a decrease of VAI values (-1.6, P < 0.001). All these differences were independent of changes in BMI and comparable in men and women. CONCLUSIONS: In conclusion, 12-month treatment with liraglutide in add-on to on-going hypoglycemic therapy significantly ameliorates all major CVD risk factors and reduces cardiometabolic risk, as estimated by VAI values.
Entities:
Keywords:
Blood pressure; Lipids; Liraglutide; Type 2 diabetes; Visceral Adiposity Index
Authors: Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad Journal: Diabetes Care Date: 2007-03-19 Impact factor: 19.112
Authors: Joe M Chehade; Rosalyn Alcalde; Emad Naem; Arshag D Mooradian; Norman C W Wong; Michael J Haas Journal: Metabolism Date: 2012-08-16 Impact factor: 8.694
Authors: David C Klonoff; John B Buse; Loretta L Nielsen; Xuesong Guan; Christopher L Bowlus; John H Holcombe; Matthew E Wintle; David G Maggs Journal: Curr Med Res Opin Date: 2008-01 Impact factor: 2.580
Authors: Rafael Simó; Bruno Guerci; Guntram Schernthaner; Baptist Gallwitz; Juan Rosas-Guzmàn; Francesco Dotta; Andreas Festa; Ming Zhou; Jacek Kiljański Journal: Cardiovasc Diabetol Date: 2015-09-04 Impact factor: 9.951